VanEck Biotech ETF (NASDAQ:BBH – Get Free Report) saw a large growth in short interest in October. As of October 30th, there was short interest totaling 60,902 shares, a growth of 51.2% from the October 15th total of 40,268 shares. Approximately 3.0% of the company’s stock are short sold. Based on an average trading volume of 14,685 shares, the days-to-cover ratio is currently 4.1 days.
VanEck Biotech ETF Stock Performance
Shares of BBH stock traded down $1.11 during trading on Tuesday, reaching $247.71. The company’s stock had a trading volume of 8,801 shares, compared to its average volume of 8,104. The business has a fifty day moving average price of $244.18 and a 200-day moving average price of $210.06. VanEck Biotech ETF has a one year low of $179.25 and a one year high of $263.74.
Institutional Investors Weigh In On VanEck Biotech ETF
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC grew its holdings in shares of VanEck Biotech ETF by 3.0% in the 1st quarter. Kestra Advisory Services LLC now owns 3,405 shares of the company’s stock valued at $640,000 after acquiring an additional 98 shares in the last quarter. Harbour Investments Inc. bought a new stake in VanEck Biotech ETF during the third quarter worth about $38,000. Global Retirement Partners LLC acquired a new position in VanEck Biotech ETF during the third quarter valued at approximately $41,000. Coastline Trust Co acquired a new position in VanEck Biotech ETF during the third quarter valued at approximately $46,000. Finally, CoreCap Advisors LLC acquired a new position in VanEck Biotech ETF during the third quarter valued at approximately $46,000. 32.05% of the stock is owned by institutional investors.
VanEck Biotech ETF Company Profile
The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.
See Also
- Five stocks we like better than VanEck Biotech ETF
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
